{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:43:02Z","timestamp":1770270182955,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T00:00:00Z","timestamp":1499126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.amjcard.2017.06.023","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T19:17:38Z","timestamp":1498677458000},"page":"931-939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)"],"prefix":"10.1016","volume":"120","author":[{"given":"Mahfouz","family":"El Shahawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Lecorps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.06.023_bib0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0015","series-title":"Praluent summary of product characteristics (EC)","author":"Sanofi","year":"2015"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0020","series-title":"Praluent\u2122 (alirocumab) injection Prescribing Information","author":"Sanofi-Aventis U.S. LLC","year":"2015"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0025","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2261-14-121","article-title":"Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials","volume":"14","author":"Colhoun","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0035","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0040","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0045","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0050","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","article-title":"Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY phase 3 clinical program trials","volume":"223","author":"Farnier","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0060","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0065","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCRESAHA.116.308811","article-title":"PCSK9 association with lipoprotein(a)","volume":"119","author":"Tavori","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CS20160403","article-title":"The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies","volume":"131","author":"Lambert","year":"2017","journal-title":"Clinical Science (London, England: 1979)"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0080","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bi7016359","article-title":"Self-association of human PCSK9 correlates with its LDLR-degrading activity","volume":"47","author":"Fan","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence","volume":"173","author":"Ferri","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0090","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/dom.12909","article-title":"Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0095","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0100","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.023_bib0105","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917310317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917310317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T06:00:08Z","timestamp":1617170408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917310317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0002914917310317"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.023","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}